| Literature DB >> 32719102 |
Alessandra Folci1, Filippo Mirabella2, Matteo Fossati1,3.
Abstract
Posttranslational modifications (PTMs) represent a dynamic regulatory system that precisely modulates the functional organization of synapses. PTMs consist in target modifications by small chemical moieties or conjugation ofEntities:
Keywords: intellectual disability; neddylation; sumoylation; synapse development; synapse function; ubiquitination
Mesh:
Substances:
Year: 2020 PMID: 32719102 PMCID: PMC7544190 DOI: 10.1523/ENEURO.0137-20.2020
Source DB: PubMed Journal: eNeuro ISSN: 2373-2822
Figure 1.Neuronal ubiquitination and ubiquitin-like modifications. , , Major components of excitatory and inhibitory synapses targeted by ubiquitin (blue squares) SUMO (purple triangles) and NEDD8 (orange hexagons) pathways. Deubiquitinating enzymes (green clamshell-like shapes) and components of the SUMO (UBC9 and SENPs) and NEDD8 machineries (NAE, UBC12, and UBE2F) are also indicated. Although NEDD8 pathway and targets are also present in the presynaptic compartment, for simplicity they are depicted in the postsynaptic region only. In , E3 ubiquitin ligases operating at excitatory synapses and their known substrates are listed in the left table. , Nuclear sumoylation and neddylation critical to synaptic function are indicated.
Figure 2.Postsynaptic control of glutamate and GABAA receptors by ubiquitination and sumoylation. UPS-dependent degradation (green arrows) of PSD-95 destabilizes surface AMPARs, resulting in enhanced receptor lateral mobility and consequently, endocytosis (box ). Ubiquitination of GluA1 and GluA2 decreases surface AMPARs through clathrin-dependent endocytosis (orange arrows). Ubiquitinated ARC is degraded via the UPS pathway. As ARC is a major regulator of AMPAR internalization, reduced ARC levels suppress AMPAR endocytosis. Conversely, sumoylated ARC triggers AMPAR internalization. Moreover, ubiquitination of intracellular GluA1-4 may also promote AMPAR sorting to the lysosomal degradation pathway (red arrows). Ubiquitination of mGlu1-5 receptors enhanced their clathrin-dependent endocytosis. Surface NMDARs are regulated by the ubiquitination pathway in a subunit-dependent manner. GluN2B undergoes a phosphorylation-dependent ubiquitination (box ), leading to UPS-dependent degradation of NMDARs. GluN2D ubiquitination enhances its degradation, although it is not clear whether it utilizes UPS-dependent or lysosomal-dependent pathways (green and red dotted arrows). Finally, ubiquitination of newly synthetized GluN1 and GluN2A results in NMDAR retrotranslocation from the ER to the cytosol and subsequent degradation through the ERAD pathway (blue arrows). Similar to GluN2D, GluK2 ubiquitination is phosphorylation-dependent and triggers its degradation through an as yet ill-defined pathway (green and red dotted arrows). In contrast, sumoylated GluK2-containing KARs are removed from the synaptic membrane via clathrin-dependent endocytosis. At inhibitory synapses, ubiquitinated γ2-containing GABAAR are sorted to the lysosomal degradation pathway, while β3-containing GABAAR are ubiquitinated in the ER and degraded through the ERAD machinery.
Rare monogenic forms of ID linked to mutations of components or regulators of the ubiquitin pathway
| Gene | Protein | Disease | Genetic abnormalities | References |
|---|---|---|---|---|
| Component of the Polycomb repressive deubiquitination (PR-DUB) complex | Bainbridge–Ropers syndrome, BRS (OMIM 615485) and ASD | |||
| Scaffolding protein stabilizing cullin RING E3 ligase | XLID (OMIM 300304) | Missense mutations | ||
| E3 ubiquitin ligase HECW2 | Neurodevelopmental disorder with hypotonia, seizures, and absent language, NDHSAL (OMIM 617268) | Missense mutations | ||
| E3 ubiquitin ligase HERC1 | Macrocephaly, dysmorphic facies, and psychomotor retardation, MDFPMR (OMIM 617011) | Missense and frameshift mutations | ||
| E3 ubiquitin ligase HERC2 | Syndrome of ID, autism, and variable neurological deficits (OMIM 615516) | Missense mutations | ||
| HECT, UBA, and WWE domain containing 1, E3 ubiquitin protein ligase | Turner type, XLID | Microduplications, missense mutations | ||
| E3 ubiquitin ligase enhancer | Prader–Willi syndrome, PWS (OMIM 176270) and Schaaf–Yang syndrome, SHFYNG (OMIM 615547) | Interstitial deletions and maternal uniparental disomy in PWS; truncating mutations in SHFYNG | ||
| Member of the TRIpartite motif (TRIM) family of RING E3 ligases | XLID (OMIM 300928) | Missense mutation | ||
| Member of the ovarian tumor domain (OTU)-containing subfamily of deubiquitinating enzymes | Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, IDDFSDA (OMIM 617452) | Truncating and missense mutations | ||
| Ubiquitin binding protein phospholipase A2 activating protein | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, NDMSBA (OMIM 617527) | Missense mutations | ||
| RNF12 E3 ubiquitin ligase | Tonne–Kalscheuer syndrome, XLID (OMIM 300978) | Missense mutation | ||
| Member of the TRIpartite motif (TRIM) family of RING E3 ligases | William–Beuren syndrome, WBS (OMIM 194050) | Microdeletion on chr. 7q11.23 | ||
| Member of the HECT domain E3 ubiquitin ligases family | ID with or without ASD (OMIM 6177520) | CNVs, missense, frameshift, splicing mutations | ||
| E2 ubiquitin conjugating enzyme E2A | XLID type Nascimento | Truncating and missense mutations | ||
| E3 ubiquitin ligase E3B | Blepharophimosis-ptosis-ID syndrome, BPIDS (OMIM 244450) | Truncating mutations | ||
| Deubiquitinating enzyme FAF-X | Female-restricted X-linked non-syndromic mental retardation-99 (OMIM 300919) | Truncating mutation and X-chr. deletion |
XLID: X-linked ID, CNV: copy number variation.